On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced DehydraTECH Delivers More CBD into the Body

  • The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets
  • DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations
  • Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than standard industry formulations. These results were confirmed in clinical lab tests conducted with live animals. LXRP has filed new patent applications based on these innovations (http://cnw.fm/k4hRO0).

The new DehydraTECH delivery platform is ideally suited for solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical, medical and supplement markets.

LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees.

In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137 percent more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://cnw.fm/rCD1R). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.

In animal tests conducted in 2018 and 2019, results showed that DehydraTECH greatly assisted in the delivery of drugs, including nicotine and cannabinoids, across the blood-brain barrier. The demonstrated effectiveness of DehydraTECH, combined with nanoemulsification, significantly expands the application of the technology for conventional dosage forms, consumable liquids and beverage dosage forms.

LXRP is a Canadian bioscience company and a drug-delivery platform innovator. The company out-licenses its disruptive delivery technology, DehydraTECH. The technology is designed to promote healthier ingestion methods and lower overall dosing. Lexaria is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and has multiple patents pending in more than 40 countries worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722